| Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
| Q90144940 | Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy? |
| Q53914428 | Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer. |
| Q36021095 | Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer |
| Q59125770 | Clinical outcomes following advanced respiratory motion management (respiratory gating or dynamic tumor tracking) with stereotactic body radiation therapy for stage I non-small-cell lung cancer |
| Q91323191 | Comparison of single- and five-fraction schedules of stereotactic body radiation therapy for central lung tumours: a single institution experience |
| Q26995851 | Complications from Stereotactic Body Radiotherapy for Lung Cancer |
| Q43191730 | Cons: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy? |
| Q36186315 | DNA topoisomerase I drugs and radiotherapy for lung cancer |
| Q99582784 | Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis |
| Q41257238 | Dosimetric comparison of carbon ion and X-ray radiotherapy for Stage IIIA non-small cell lung cancer |
| Q36451644 | Dosimetric evaluation of the feasibility of stereotactic body radiotherapy for primary lung cancer with lobe-specific selective elective nodal irradiation |
| Q61443804 | Early stage non-small cell lung cancer treated with pencil beam scanning particle therapy: retrospective analysis of early results on safety and efficacy |
| Q37151785 | Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree |
| Q57058757 | Final report of survival and late toxicities in the Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702) |
| Q42668963 | Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation |
| Q38990272 | Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer |
| Q36235727 | LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective |
| Q33780233 | Malignant tracheal necrosis and fistula formation following palliative chemoradiotherapy: a case report |
| Q48202266 | Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1). |
| Q92602008 | Pre-treatment serum bicarbonate predicts for primary tumor control after stereotactic body radiation therapy in patients with localized non-small cell lung cancer |
| Q36241814 | Pros: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy? |
| Q37367501 | Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules |
| Q33571109 | Retrospective analysis of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) in comparison with a contemporaneous cohort of primary lung lesions (PLLs) |
| Q92973685 | Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer |
| Q42363621 | Simultaneous integrated protection : A new concept for high-precision radiation therapy |
| Q30241812 | Specific toxicity after stereotactic body radiation therapy to the central chest : A comprehensive review |
| Q55224635 | Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk? |
| Q57172947 | Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances |
| Q37348287 | Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute. |
| Q53054421 | Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. |
| Q38155155 | Stereotactic body radiotherapy for early stage lung cancer |
| Q37109702 | Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes |
| Q53125428 | Surgery or radiotherapy for early-stage lung cancer--a potential comparison bias. |
| Q43798893 | Surgery versus SABR for NSCLC. |
| Q38227883 | The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metasta |
| Q26853124 | Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy? |
| Q93369476 | Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors |
| Q55441971 | [Stereotactic Body Radiotherapy for Centrally Located Non-small Cell Lung Cancer]. |